LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on Latin America, announced that its mobile healthcare application has entered its final development stage, with the company completing testing, optimization, and deployment preparations. The app is expected to be submitted for distribution and become available through the Apple App Store and Google Play in the coming weeks, subject to platform review and technical requirements.
This transition from development to public availability is a significant milestone for the company, as the app will serve as the primary mobile access point to its digital healthcare ecosystem. The application aims to provide users with a convenient interface to access supported healthcare services, digital tools, and additional functionality as the platform expands. The development team is focused on final technical testing, interface optimization, and platform compatibility reviews.
Once available, the app is expected to offer a scalable mobile foundation for introducing new healthcare-related features, including patient-facing tools, healthcare-provider interaction, digital communications, access to medical and wellness information, and healthcare-service coordination. LataMed AI believes mobile accessibility is crucial in Latin America, where smartphones are a primary means of accessing digital services. By launching on both major app marketplaces, the company intends to provide a direct and accessible way for users to engage with its healthcare ecosystem.
The app also supports the company's long-term strategy of connecting patients, healthcare professionals, pharmacies, insurers, payment providers, and wellness organizations within an integrated digital healthcare environment. LataMed AI continues to develop its AI-supported technologies, including CardioAI, PulmoAI, and NeuroAI, and plans for the mobile infrastructure to eventually offer an additional pathway for users and professionals to interact with these tools, subject to development and regulatory approvals.
“Our mobile application is now moving from development toward deployment, and we believe we are approaching an important milestone for LataMed AI,” said Dr. Kevin Rodan Levy, CEO. “Our team is completing the final stages of testing and preparation, and we currently expect the application to become available through the Apple App Store and Google Play in the coming weeks, subject to the applicable platform review processes.” Dr. Levy added, “Mobile availability is important because it provides a direct connection between users and the digital healthcare ecosystem we are building. Our objective is to create a platform that is practical, accessible and capable of expanding as we continue introducing additional healthcare services and artificial intelligence-supported tools.”
The anticipated release represents another step in moving LataMed AI's technology from development into user-facing digital healthcare infrastructure. Following the initial release, the company plans to evaluate additional functionality, platform integrations, and user-facing tools for future versions. The company expects to provide updates on submission and availability as milestones are completed. For more information, visit https://latamed.ai or review SEC filings at www.sec.gov.
